Skip to content

Gyre Therapeutics

Primary Menu

About
Science
Investors
Contact

Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa

Post navigation

Previous: Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia

Next: Crimson 1 Study: Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptacog alfa (activated) for on-demand treatment and control of bleeding episodes in subjects with hemophilia A or hemophilia B, with inhibitors

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

About
- Management Team
- Board of Directors
Science
Investors
Contact

Gyre Therapeutics

Gyre Therapeutics, Inc.
| 12770 High Bluff Drive, Suite 150,
San Diego, CA 92130

© Gyre Therapeutics, Inc. All rights reserved.
Terms of Use Privacy Policy

X

Previous

Next